ENTITY
Bristol-Myers Squibb

Bristol-Myers Squibb (BMY UN)

2
Analysis
Health CareUnited States
Bristol-Myers Squibb Company is a global biopharmaceutical company. The Company develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. Bristol Myers Squibb focuses on products and experimental therapies address cancer, heart disease, HIV and AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.
more
Refresh
08 Nov 2017 20:24

Genomics as an Investment Theme

Genomics as an investment theme Costs of sequencing a human genome have fallen to less than $1,000 China leads the world in gene sequencing The...

Logo
305 Views
Share
bearishDaiichi Sankyo
14 Sep 2017 07:49

Daiichi Sankyo (4568 JP) Releases Phase I Data for DS-8201 at ESMO 2017

Daiichi Sankyo [DSK] (4568 JP) released Phase I data for DS-8201 at ESMO 2017 as follows: 32% overall response rate, 82% disease control rate. The...

13 Sep 2017 22:59

Biosimilar Battlefield: Samsung Bioepis Forecast

This Insight uses the biosimilar market model discussed in Surveying The Biosimilar Battlefield to build a long-term revenue forecast for the...

Share
bullishPeptidream Inc
11 Apr 2017 21:53

PeptiDream: J&J Latest Drug Major to Tie Up

On the surface, Peptidream's (4587 JP) deal with Johnson & Johnson's (JNJ US) Janssen unit looks no different from the deals they have cut with...

10 Apr 2017 16:15

Sosei & Kyowa Hakko Kirin: Positive News on GPCR Drugs

Kyowa Hakko Kirin's (4151 JP) announcement that “moga” – mogamulizumab (KW-0761) – has met its primary endpoint (PFS) in Phase III trials for...

x